Menger, MarcusMarcusMengerDreymann, NicoNicoDreymannWünsche, JuliaJuliaWünsche2025-05-012025-05-012023-06-14https://publica.fraunhofer.de/handle/publica/487188In a first aspect, the invention relates to a DNA aptamer comprising a polynucleotide sequence having at least 70 % identity to a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO: 10 and SEQ ID NO: 11 for use as a medicament, especially for use in treatment of cancer and/or prevention of cancer in a subject. The DNA aptamers are able to inhibit binding of Urokinase type plasminogen activator (uPA) with Urokinase type plasminogen activator receptor (uPAR) and are also able to inhibit activity of Urokinase type plasminogen activator (uPA). A second aspect of the invention relates to the DNA aptamer, used according to the first aspect, itself. A third aspect of the invention is related to a method for identifying a subject benefiting from cancer treatment with a DNA aptamer according to the first aspect and of the second aspect respectively. In a fourth aspect, the invention relates to a kit comprising a DNA aptamer according to the first aspect and of the second aspect respectively.enpatentEP4194555 A1EP20210213412